Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Boehringer Ingelheim acquires AMAL Therapeutics, significantly enriching its cancer immunology portfolio with a novel cancer vaccines platform; deal worth up…
Boehringer Ingelheim acquires AMAL Therapeutics for its KISIMA immunization platform; EUR 225M upfront and developmental milestones plus up to EUR 100M in…
Preliminary KISIMA-01 Phase 1b data showed ATP128 was well tolerated alone and with ezabenlimab, with antigen-specific immune responses and increased TIL…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Boehringer Ingelheim acquired AMAL Therapeutics for up to EUR 325M (EUR 225M upfront and development milestones plus EUR 100M commercial milestones; ~$366M), adding the KISIMA cancer vaccine platform with lead asset ATP128 in colorectal cancer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA (this deal) | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / NBE Therapeutics | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2019 deals · Boehringer Ingelheim GmbH deals · Oncology deals